TP53 and diffuse large B-cell lymphoma: The frequency of somatic variants detected was consistent with prior DLBCL sequencing efforts [1] and included a high rate in targets of aberrant somatic hypermutation [22] (e.g., IGLL5, PIM1), mutations in genes that convey therapeutic resistance (e.g., TP53) [23] and those associated with susceptibility to targeted therapies (e.g., EZH2Y646) [24].